The Weekly Term Sheet (29)
For large pharmaceutical firms, the week’s deals underscored a willingness to spend on promising science – especially to hedge against
Nvidia, AMD, and the Battle for Biotech AI Hardware in 2025
The biotech industry’s appetite for artificial intelligence has grown insatiable. From AI-driven drug discovery and protein folding to generative
Biotech’s NATO moment: The cock crowed, but will the sun rise?
In June 2025, NATO quietly co‑led a US $35 million Series A funding round for Portal Biotech, a UK
AI in Pharma 2025: Hype, Reality, and the Road Ahead
Artificial intelligence (AI) has permeated the pharmaceutical industry with promises to transform everything from drug discovery to clinical trials. By
Global Clinical Trial Outlook for Late 2025 – Key Readouts and Market Implications
The second half of 2025 is poised to deliver a wave of critical clinical trial readouts across the biopharmaceutical industry.
The Long Quest to Defeat Alzheimer’s – The State of Dementia Research in 2025
Alzheimer’s disease, the most common form of dementia, poses one of the greatest challenges in modern medicine. Every year,
Recursive Evidence and the Fat-Tailed Risk of HTA Circularity
It begins, as all good policies do, with a peer-reviewed article. A study from 2013 estimates the cost of a
New Funds on the Block: The First-Half Year Check-In on Biotech VC & PE
The first half of 2025 has seen a wave of new venture capital (VC) and private equity (PE) funds dedicated
What Are Drug Targets? A Sceptic’s Guide to Molecular Bullseyes
1. Introduction: The Gospel of the Target
In the parlance of modern pharmaceuticals, few words carry the theological weight of
The Algorithmic Mirage: How AI's Promise in Drug Discovery Risks Inflating Expectations
I. Introduction: The Double-Edged Scalpel of AI in Drug Discovery
The relentless pursuit of new medicines remains a cornerstone of
